Vera Therapeutics (NASDAQ:VERA) Shares Gap Up - Here's Why

Key Points

• Vera Therapeutics shares jumped 7.4%, opening at $31.29 versus a prior close of $28.89, amid renewed investor attention.
• HC Wainwright maintained a Buy rating but cut its price target from $125 to $90, citing lower long-term EPS forecasts, while Wedbush offered a more cautious outlook. Analysts’ overall consensus remains “Moderate Buy”, with an average target of $81.15.
• Vera reported quarterly EPS of -$1.52, beating the consensus estimate of -$1.58, but analysts expect a full-year loss of approximately $6.45 per share.

Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report)'s share price gapped up before the market opened on Friday . The stock had previously closed at $28.89, but opened at $31.29. Vera Therapeutics shares last traded at $30.4680, with a volume of 1,790,077 shares trading hands.

Key Stories Impacting Vera Therapeutics

Here are the key news stories impacting Vera Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to a loss of $6.52 from a loss of $6.79 and modestly improved estimates for the third and fourth quarters of 2026. These revisions suggest somewhat better near-term profitability than previously expected. HC Wainwright Lowers Vera Therapeutics Price Target to $90
• Positive Sentiment: The firm continues to project a path toward profitability, forecasting positive EPS of $0.49 in FY2028, $5.21 in FY2029 and $8.79 in FY2030. The $90 target remains well above recent trading levels, providing a bullish valuation signal if Vera’s pipeline and commercial prospects develop as expected.
• Neutral Sentiment: HC Wainwright left its Buy rating intact but lowered its price target to $90, indicating that the analyst remains constructive while acknowledging reduced valuation or earnings expectations. HC Wainwright Lowers Vera Therapeutics Price Target to $90
• Negative Sentiment: The analyst cut FY2027 EPS expectations to a loss of $4.38 from a loss of $3.84, FY2028 EPS to $0.49 from $2.20, FY2029 EPS to $5.21 from $9.11, and FY2030 EPS to $8.79 from $10.83. The sharp reductions imply a slower earnings ramp and may temper investor enthusiasm.
• Negative Sentiment: Separate recent coverage from Wedbush was characterized as a pessimistic forecast for Vera Therapeutics, adding caution to the otherwise supportive HC Wainwright rating. Wedbush Issues Pessimistic Forecast for Vera Therapeutics

Analyst Ratings Changes

A number of analysts have issued reports on the company. The Goldman Sachs Group reaffirmed a "buy" rating and issued a $90.00 price objective on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. HC Wainwright lowered their target price on Vera Therapeutics from $125.00 to $90.00 and set a "buy" rating for the company in a research report on Wednesday. William Blair reissued an "outperform" rating on shares of Vera Therapeutics in a report on Tuesday, June 2nd. TD Cowen boosted their price target on shares of Vera Therapeutics from $73.00 to $78.00 and gave the stock a "buy" rating in a research report on Wednesday, July 8th. Finally, Evercore set a $91.00 price target on shares of Vera Therapeutics in a research note on Friday, May 15th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Vera Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $81.15.

Vera Therapeutics Stock Up 7.4%

The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.15. The company has a 50 day simple moving average of $36.40 and a two-hundred day simple moving average of $38.56. The company has a market capitalization of $2.23 billion, a P/E ratio of -5.34 and a beta of 0.92.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The company reported ($1.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.58) by $0.06. During the same period in the prior year, the business earned ($1.20) earnings per share. As a group, equities analysts predict that Vera Therapeutics, Inc. will post -6.45 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Marshall Fordyce sold 46,250 shares of the stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $42.30, for a total transaction of $1,956,375.00. Following the sale, the chief executive officer owned 151,994 shares in the company, valued at approximately $6,429,346.20. This represents a 23.33% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 15.90% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Los Angeles Capital Management LLC bought a new stake in shares of Vera Therapeutics in the 4th quarter worth about $46,000. Aster Capital Management DIFC Ltd purchased a new position in shares of Vera Therapeutics during the 4th quarter worth about $71,000. Quantbot Technologies LP bought a new position in Vera Therapeutics during the 2nd quarter valued at about $51,000. Sandia Investment Management LP bought a new position in Vera Therapeutics during the 4th quarter valued at about $127,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in Vera Therapeutics by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,106 shares of the company's stock worth $157,000 after purchasing an additional 639 shares during the period. Institutional investors own 99.21% of the company's stock.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body's own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source